X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs AJANTA PHARMA - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA AJANTA PHARMA GSK PHARMA/
AJANTA PHARMA
 
P/E (TTM) x 67.5 21.6 312.5% View Chart
P/BV x 13.6 5.1 267.8% View Chart
Dividend Yield % 2.1 0.0 -  

Financials

 GSK PHARMA   AJANTA PHARMA
EQUITY SHARE DATA
    GSK PHARMA
Mar-18
AJANTA PHARMA
Mar-18
GSK PHARMA/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs2,7601,818 151.8%   
Low Rs2,0401,106 184.4%   
Sales per share (Unadj.) Rs339.0239.5 141.6%  
Earnings per share (Unadj.) Rs41.452.8 78.5%  
Cash flow per share (Unadj.) Rs45.959.5 77.1%  
Dividends per share (Unadj.) Rs35.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs242.9230.0 105.6%  
Shares outstanding (eoy) m84.7088.77 95.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.16.1 116.0%   
Avg P/E ratio x57.927.7 209.2%  
P/CF ratio (eoy) x52.324.6 212.8%  
Price / Book Value ratio x9.96.4 155.4%  
Dividend payout %84.50-   
Avg Mkt Cap Rs m203,280129,782 156.6%   
No. of employees `000NA6.8 0.0%   
Total wages/salary Rs m5,2343,765 139.0%   
Avg. sales/employee Rs ThNM3,128.4-  
Avg. wages/employee Rs ThNM554.0-  
Avg. net profit/employee Rs ThNM689.7-  
INCOME DATA
Net Sales Rs m28,71521,258 135.1%  
Other income Rs m545242 225.8%   
Total revenues Rs m29,26021,499 136.1%   
Gross profit Rs m5,0596,584 76.8%  
Depreciation Rs m380596 63.8%   
Interest Rs m24 48.8%   
Profit before tax Rs m5,2226,226 83.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1780-   
Tax Rs m1,8921,539 122.9%   
Profit after tax Rs m3,5084,686 74.9%  
Gross profit margin %17.631.0 56.9%  
Effective tax rate %36.224.7 146.6%   
Net profit margin %12.222.0 55.4%  
BALANCE SHEET DATA
Current assets Rs m21,81512,236 178.3%   
Current liabilities Rs m15,9993,461 462.3%   
Net working cap to sales %20.341.3 49.1%  
Current ratio x1.43.5 38.6%  
Inventory Days Days6460 105.6%  
Debtors Days Days1984 22.1%  
Net fixed assets Rs m12,47511,140 112.0%   
Share capital Rs m847177 478.8%   
"Free" reserves Rs m19,72620,237 97.5%   
Net worth Rs m20,57320,414 100.8%   
Long term debt Rs m610 59.4%   
Total assets Rs m39,47524,486 161.2%  
Interest coverage x2,612.01,519.4 171.9%   
Debt to equity ratio x00 58.9%  
Sales to assets ratio x0.70.9 83.8%   
Return on assets %8.919.2 46.4%  
Return on equity %17.123.0 74.3%  
Return on capital %26.230.5 86.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56411,667 4.8%   
Fx outflow Rs m7,4291,616 459.9%   
Net fx Rs m-6,86510,052 -68.3%   
CASH FLOW
From Operations Rs m4,7282,854 165.7%  
From Investments Rs m-1,042-2,604 40.0%  
From Financial Activity Rs m-3,066-2 153,320.0%  
Net Cashflow Rs m620248 249.8%  

Share Holding

Indian Promoters % 0.0 73.8 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 1.6 658.1%  
FIIs % 23.8 7.6 313.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 17.0 90.6%  
Shareholders   102,036 20,968 486.6%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  ELDER PHARMA  SANOFI INDIA  DR. DATSONS LABS  

Compare GSK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 11.6% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 11.6% YoY). Sales on the other hand came in at Rs 5 bn (up 8.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 235.3% (Quarterly Result Update)

Jul 26, 2018 | Updated on Jul 26, 2018

For the quarter ended June 2018, GSK PHARMA has posted a net profit of Rs 886 m (up 235.3% YoY). Sales on the other hand came in at Rs 7 bn (up 21.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

Revenge of the Ratings Agencies(Vivek Kaul's Diary)

Sep 7, 2018

Do you remember when ratings agencies ruled financial markets? Nick explains why he thinks it's time to prepare yourselves for a comeback of the ratings agencies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Sep 19, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE GSK PHARMA WITH

MARKET STATS